Immediate Impact
20 standout
Citing Papers
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
2025 Standout
Endoplasmic reticulum stress as a driver and therapeutic target for kidney disease
2025 Standout
Works of Chenghao Chu being referenced
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele
2023 Standout
Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events
2023
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Chenghao Chu | 115 | 29 | 20 | 23 | 17 | 245 | |
| Charlotte Salmon Gandonnière | 49 | 16 | 11 | 22 | 16 | 199 | |
| Candace Carter | 56 | 21 | 5 | 42 | 12 | 260 | |
| Danielle Armas | 69 | 72 | 8 | 27 | 17 | 295 | |
| Elissa Thorner | 49 | 16 | 6 | 33 | 22 | 230 | |
| Helen Heacock | 51 | 25 | 1 | 15 | 11 | 262 | |
| Mark Dunn | 47 | 37 | 2 | 11 | 12 | 225 | |
| Catherine John | 95 | 61 | 4 | 5 | 22 | 253 | |
| Jean Temeck | 17 | 36 | 25 | 113 | 10 | 258 | |
| Rebecca M. Joseph | 29 | 9 | 12 | 12 | 19 | 278 | |
| Mary Tran | 31 | 64 | 5 | 7 | 21 | 217 |
All Works
Login with ORCID to disown or claim papers
Loading papers...